¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immunization, serum hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pooled serum
    鴂͂֞
  • preimmune serum
    ¸é¿ªÀÌÀüÇ÷û
  • specific serum
    ƯÀÌÇ÷û
  • standard serum
    ±âÁØÇ÷û
  • serum
    Ç÷û
  • serum accident
    Ç÷û»ç°í
  • serum amylase
    Ç÷û¾Æ¹Ð¶ó¾ÆÁ¦
  • serum imbibition
    Ç÷ûÈí¼ö
  • serum intoxication
    Ç÷ûÁßµ¶
  • serum rash
    Ç÷û¹ßÁø
  • serum separator tube
    Ç÷ûºÐ¸®°ü
  • serum shock
    Ç÷û¼îÅ©
  • serum sickness
    Ç÷ûº´
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
  • serum-fast
    Ç÷ûÀúÇ×¼º-
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hepatitis carrier state
    °£¿°º¸±ÕÀÚ»óÅÂ
  • infantile hepatitis
    ¿µ¾Æ°£¿°
  • infectious hepatitis
    Àü¿°°£¿°, ¿¡ÀÌÇü°£¿°
  • lupus hepatitis
    ·çǪ½º°£¿°
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°°£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • non-A, non-B hepatitis
    ¿¡À̺ñÀ̿ܰ£¿°
  • post-transfusion hepatitis
    ¼öÇ÷Èİ£¿°
  • suppurative hepatitis
    È­³ó°£¿°
  • toxic hepatitis
    µ¶¼º°£¿°
  • toxipathic hepatitis
    µ¶¹°¼º°£¿°
  • transfusion hepatitis
    (¢¡post-transfusion hepatitis) ¼öÇ÷Èİ£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×Ç÷ûºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiplatelet serum
    Ç×Ç÷¼ÒÆÇÇ÷û(¡­úìôè).
  • antirabies serum
    Ç×±¤°ßº´Ç÷û(ù÷ÎÊ̳ܻ úìôè).
  • antitetanic serum
    ÇׯĻódzÇ÷û(¡­úìôè).
  • antithymocyte serum
    Èä¼±¼¼Æ÷Ç×Ç÷û, °¡½¿»ù¼¼Æ÷Ç×Ç÷û
  • antitoxic serum
    Ç×µ¶¼Ò(¼º) Ç÷û(¡­úìôè).
  • antitoxic serum
    Ç×µ¶¼Ò(¼º) Ç÷û(¡­úìôè).
  • antitoxic serum
    Ç×µ¶(¼Ò)¼º Ç÷û
  • globulin, immune serum
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°
  • homologous serum jaundice
    µ¿·ùÇ÷û¼º Ȳ´Þ.
  • horse anti serum thymocyte
    ¸¶Ç×Ç÷ûÈä¼±¼¼Æ÷.
  • horse anti serum thymocyte
    ¸»Ç×Ç÷ûÈä¼±¼¼Æ÷.
  • horse serum
    ¸»Ç÷û(¡­úìôè).
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cholestatic hepatitis
    ´ãÁó¿ïü¼º °£¿°, ´ãÁóÁ¤Ã¼¼º °£¿°.
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿¼º °£¿°(¡­ÊÜæú).
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic hepatitis
    ¸¸¼º °£¿°
  • chronic hepatitis
    ¸¸¼º°£¿°
  • chronic hepatitis B
    ¸¸¼º BÇü °£¿°
  • chronic persistent hepatitis
    ¸¸¼º Áö¼Ó¼º °£¿°
  • delta (¥ä) hepatitis virus
    µ¨Å¸°£¿°¹ÙÀÌ·¯½º
  • delta hepatitis
    µ¨Å¸°£¿°(DÇü°£¿°)(¡­ÊÜæú)
  • delta hepatitis.
    d Çü °£¿°, µ¨Å¸°£¿°
  • drug-induced hepatitis
    ¾à¹°¼º °£¿°(¡­°£¿°).
  • drug-induced hepatitis
    ¾à¹° [¼ÒÈ­]¾à¹°¼º °£¿°(¡­ÊÜæú).
  • drug-induced hepatitis
    ¾à¹° ¼ÒÈ­¾à¹°¼º °£¿°(¡­ÊÜæú).
  • epidemic hepatitis
    À¯Ç༺ °£¿°.
  • epizootic hepatitis
    µ¿¹°À¯Ç༺ °£¿°.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
CAH chronic active hepatitis; chronic aggressive hepatitis; combined atrial hypertrophy; congenital adre...
HA H antigen; Hakim-Adams [syndrome]; halothane anesthesia; Hartley [guinea pig]; headache; health alli...
HBV hepatitis B vaccine; hepatitis B virus
HDV hepatitis D virus; hepatitis delta virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HCV Anti-hepatitis C virus
anti-HCV Anti-hepatitis-C-virus
anti-HCV Antibodies against hepatitis C virus
anti-HAV Antibodies to hepatitis A virus
anti-HBc Antibodies to hepatitis B core antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • serum albumin
    Ç÷û ¾ËºÎ¹Î
    Ç÷û Áß ÃÑ ´Ü¹éÁúÀÇ ¾à 60%¸¦ Â÷ÁöÇÏ°í »ý¸®ÇÐÀû ¿ªÇÒÀº »ïÅõ¾ÐÀÇ À¯ÁöÀÌ´Ù.
  • serum alkaline phosphatase
    Ç÷û ¾ËÄ«¸® Æ÷½ºÆÄŸ¾ÆÁ¦
  • serum amyloid protein A
    Ç÷û ¾Æ¹Ð·ÎÀ̵å ÇÁ·Îƾ A
  • serum bile acid
    Ç÷û ´ãÁó»ê
    ¹Ì·® Á¸ÀçÇÑ´Ù.
  • serum chloride
    Ç÷û Ŭ·Î¶óÀ̵å
    Á¤»óÄ¡´Â 96-109 mEq/ml ÀÌ´Ù.
  • serum cholesterol fraction
    Ç÷û ÄÝ·¹½ºÅ×·Ñ ºÐȹ
    Ç÷û Áß ÃÑÄÝ·¹½ºÅ×·ÑÀº Æò±Õ 200mg 100ml ¿¡½ºÅÍÈ­µÇÁö ¾ÊÀº À¯¸®ÇÑ ÄÝ·¹½ºÅ×·ÑÀº Æò±Õ 55mgÀÌ´Ù.
  • serum cholinesterase
    Ç÷û Äݸ°¿¡½ºÅ×¶óÁ¦
  • serum colloidal reaction
    Ç÷û ±³Áú ¹ÝÀÀ
    °£ ±â´É °Ë»çÀÇ Á¾·ù.
  • serum complement titer
    Ç÷û º¸Ã¼ °¡ÃøÁ¤
    ¸ðµç º¸Ã¼ Ȱ¼ºÀÇ ÃÑÇÕÀ¸·Î¼­ ÃøÁ¤µÈ´Ù.
  • serum creatine
    Ç÷û Å©·¹¾ÆÆ¾
    ¿äÁß Å©·¹¾ÆÆ¾ÀÇ ¼º¼è¿Í °ÅÀÇ °°Àº ÀÇÀǸ¦ Áö´Ñ´Ù.
  • serum diastase activity
    Ç÷û µð¾Æ½ºÅ¸Á¦Ä¡
    Ç÷û¿¡ ÇÔÀ¯µÈ ¾Æ¹Ð¶ó¾ÆÁ¦ÀÇ ¾çÀ» ³ªÅ¸³»´Âµ¥ »ç¿ëÇÑ´Ù.
  • serum electrolyte
    Ç÷û ÀüÇØÁú
    ü¾×ÀÇ »ê ¿°±â ÆòÇü, »ïÅõ¾Ð À¯Áö¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÑ´Ù.
  • serum folate
    Ç÷û ¿±»ê¿°
  • serum free fatty acid
    Ç÷û À¯¸® Áö¹æ»ê Á¤·®
    Á¤»óÄ¡´Â Á¶±â °øº¹ ½Ã 200-600¥ìEq/l·Î »ý¸®Àû º¯µ¿ÀÌ Å©´Ù.
  • serum iron
    Ç÷û ö
    Ç÷û ³»¿¡ Á¸ÀçÇϴ ö.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
immunization, dt DT (diphtheria and tetanus) vaccine does not protect from pertussis and is usually reserved for individuals who have had a significant adverse reaction to a dpt shot or who have a personal or family history of a seizure disorder or brain disease.
(12 Dec 1998)
immunization, dtap Like DPT, DTaP protects from diphtheria, pertussis (whooping cough) and tetanus. Dtap is the same as dtp, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. Dtap is currently recommended only for the shots given at 18 months and 4-6 years of age.
(12 Dec 1998)
immunization, flu The flu (influenza) vaccine is recommended for persons at high risk for serious complications from influenza infection, including everyone 65 or over; people with chronic diseases of the heart, lung or kidneys, diabetes, immunosuppression, or severe forms of anaemia; residents of nursing homes and other chronic-care facilities, children and teenagers taking aspirin therapy (and who may therefore be at risk for developing reye syndrome after an influenza infection), and those in close or frequent contact with anyone at high risk. Persons with an allergy to eggs should not receive influenza vaccine.
(12 Dec 1998)
immunization, german measles See Immunization, MMR.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
immunization, h. flu See Immunization, HIB.
(12 Dec 1998)
immunization, hib This vaccine is to prevent disease caused by the haemophilus influenzae type b (hib) bacteria. The h. Influenzae (h. Flu) bacteria can cause a range of serious diseases including meningitis with potential brain damage and epiglottitis with airway obstruction poisoning. The hib vaccine is usually given at 2, 4 and 6 months of age. A final booster is given at 12-15 months of age. Hib vaccine rarely causes severe reactions.
(12 Dec 1998)
immunization, influenza See Immunization, flu.
(12 Dec 1998)
immunization, measles See Immunization, MMR.
(12 Dec 1998)
immunization, mmr The standard vaccine given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most u.s. Colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
immunization, mumps See Immunization, MMR.
(12 Dec 1998)
immunization, passive Transfer of immunity from immunised to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (adoptive transfer).
(12 Dec 1998)
immunization, pneumococcal pneumonia This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease (copd) or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children.
(12 Dec 1998)
immunization, polio The vaccines available for vaccination against polio are opv (oral polio vaccine) and ipv (inactivated polio vaccine). Opv is still the preferred vaccine for most children. As its name suggests, it is given by mouth. Ipv, or inactivated polio vaccine is given as a shot in the arm or leg. Infants and children should be given four doses of opv. The doses are given at 2 months, 4 months, 6-18 months and 4-6 years of age. Persons allergic to eggs or the drugs neomycin or streptomycin should receive opv, not the injectable ipv. Conversely, ipv should be given if the vaccine recipient is on long-term steroid (cortisone) therapy, has cancer, or is on chemotherapy or if a household member has aids or there is an unimmunised adult in the house.
(12 Dec 1998)
immunization program Organised services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á